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TheGprotein-coupled receptor TGR5 has been iden-
tified as an important component of the bile acid
signaling network, and its activation has been linked
to enhanced energy expenditure and improved gly-
cemic control. Here, we demonstrate that activation
of TGR5 in macrophages by 6a-ethyl-23(S)-methyl-
cholic acid (6-EMCA, INT-777), a semisynthetic BA,
inhibits proinflammatory cytokine production, an
effect mediated by TGR5-induced cAMP signaling
and subsequent NF-kB inhibition. TGR5 activation
attenuated atherosclerosis in Ldlr/Tgr5+/+ mice
but not in Ldlr/Tgr5/ double-knockout mice.
The inhibition of lesion formation was associated
with decreased intraplaque inflammation and less
plaque macrophage content. Furthermore, Ldlr/
animals transplanted with Tgr5/ bone marrow did
not show an inhibition of atherosclerosis by INT-
777, further establishing an important role of leuko-
cytes in INT-777-mediated inhibition of vascular
lesion formation. Taken together, these data attribute
a significant immune modulating function to TGR5
activation in the prevention of atherosclerosis, an
important facet of the metabolic syndrome.
INTRODUCTION
Bile acids (BAs), the main excretion products of cholesterol, are
emerging as pleiotropic signaling molecules (Pols et al., 2011;
Russell, 2009). Besides the well-established role of BAs in the
activation of the nuclear receptor farnesoid X receptor (FXR)
(reviewed in Modica et al., 2010), BAs also activate the cell
membrane receptor TGR5 (also known as GPBAR1 or
GPR131) (Kawamata et al., 2003; Maruyama et al., 2002). Activa-
tion of TGR5 signaling controls several physiological pathways
relevant to metabolic homeostasis, including the enhancement
of energy expenditure through the induction of type 2 deiodinase
in brown adipocytes (Watanabe et al., 2006) and improvement ofCell Mglucose tolerance through its commanding role on GLP-1 secre-
tion from enteroendocrine cells (Thomas et al., 2009). In the liver,
TGR5 activation protects against the development of hepato-
steatosis (Katsuma et al., 2005; Thomas et al., 2009; Vassileva
et al., 2010), while in the gallbladder, it modulates chloride and
fluid secretion and stimulates smooth muscle relaxation (Keitel
et al., 2009; Lavoie et al., 2010; Li et al., 2011).
Atherosclerosis is a chronic disorder of the vessel wall that
underpins the development of important vascular diseases,
such as coronary artery and cerebrovascular disease (Rocha
and Libby, 2009). The development and progression of athero-
sclerosis is enhanced by dyslipidemia and chronic inflammation,
in which macrophages are proposed to play an important role
(Rocha and Libby, 2009). The latter cells scavenge modified
forms of LDL in the vessel wall, eventually resulting in foam cell
formation and local production of cytokines and chemokines
that initiate chronic inflammation of the vessel wall, one of the
initial steps in the pathogenesis of atherosclerosis. Interestingly,
TGR5 is expressed in several immune cells, such as monocytes,
alveolar macrophages, and Kupffer cells (Kawamata et al., 2003;
Keitel et al., 2008), and it has been demonstrated that BAsmodu-
late the inflammatory response in these cells. In agreement with
these observations, it was recently shown that TGR5 activation
inhibits the inflammatory response in the liver (Wang et al., 2011).
We hypothesized that TGR5 might have a role in the develop-
ment of atherosclerosis and hence investigated the expression
and function of TGR5 in macrophages, within the context of
atherosclerosis. ByusingTGR5 loss- andgain-of-functionmouse
models, in combination with a pharmacological approach to
change TGR5 activity, we here demonstrate an important role
of TGR5 in the modulation of macrophage-mediated inflamma-
tion and in the development of atherosclerosis. Our work hence
demonstrates that TGR5 may be a promising target for immune
modulation,whichcouldbeexploited toprevent thedevelopment
of atherosclerosis, an important facet of themetabolic syndrome.
RESULTS
The TGR5 Agonist INT-777 Inhibits
Macrophage Inflammation
In our previous studies, we showed that TGR5activation protects
mice from obesity and insulin resistance, two major hallmarks ofetabolism 14, 747–757, December 7, 2011 ª2011 Elsevier Inc. 747
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2006). As chronic inflammation also significantly contributes to
the progression of the metabolic syndrome, we initially explored
the immune regulatory function of TGR5 in vivo. To do so, we in-
jected mice intraperitoneally with lipopolysaccharide (LPS) and
took blood of these animals. Serum TNFa levels were increased
2 hr after LPS, an effect that was more pronounced in Tgr5/
animals as compared to Tgr5+/+ animals (Figure S1A available
online). We then assessed expression of TGR5 in several inflam-
matory cell populations and other tissues, isolated after thiogly-
collate-injection in the peritoneal cavity of C57Bl/6J mice. Cells
were subsequently stained with specific antibodies allowing
fluorescence-activated cell sorting (FACS) of B cells, T cells,
granulocytes, and macrophages. Tgr5 messenger RNA (mRNA)
was detected in all tissues, including different immune cell popu-
lations,with various degreesof expression (FigureS1B). Asprevi-
ously reported, Tgr5was highly enriched in the gallbladder (Keitel
et al., 2009; Vassileva et al., 2006). Most notably, Tgr5 was
expressed in the sortedCD11b+Gr–macrophagepopulation (Fig-
ure S1B), and could also be detected in several macrophage cell
lines, and in cultured primary thioglycollate-elicited peritoneal
macrophages (FigureS1C).Moreover,RAW264.7cells transfected
with a green fluorescent protein (GFP)-tagged human Tgr5
construct showed that TGR5 localized to the cell membrane in
macrophages as observed by confocal microscopy (Figure S1D).
We next treated cells with the TGR5-specific semisynthetic
BA, INT-777, and subsequently measured calcium flux and intra-
cellular cAMP levels to investigate whether TGR5 is responsive in
these cells. Consistent with reports in other cells (Keitel et al.,
2009), INT-777 increased cAMP levels about 4-fold and induced
a transient increase in cytosolic calcium in primarymacrophages
isolated from Tgr5+/+ mice, which was not observed in INT-777-
treated macrophages isolated from Tgr5/mice and confirmed
the presence of functional agonist-responsive TGR5 in macro-
phages (Figures 1A and 1B).
We then stimulated primary macrophages from Tgr5+/+ and
Tgr5/ mice with LPS. Gene expression levels of Tnfa and
Il-1b (Figure 1CandFigure S1E), aswell as secreted TNFaprotein
(Figure 1D), were more induced in the Tgr5/ relative to Tgr5+/+
mice upon LPS stimulation. Conversely, the TNFa response to
LPS was reduced in macrophages overexpressing TGR5, iso-
lated from Tgr5 transgenic mice, as compared to wild-type
macrophages (Figures 1E and 1F). In addition, INT-777 treatment
of Tgr5 transgenic macrophages resulted in an even further
reduction of TnfamRNA levels as compared to wild-type macro-
phages (Figure S1F). These data suggest a critical role of TGR5
activation in modulating the cytokine response of macrophages.
To further investigate whether TGR5 activation inhibits cytokine
production of macrophages, we exposed RAW264.7 cells to
INT-777 and subsequently stimulated cytokine production using
LPS. LPS increased themRNA levels of inflammatory cytokines in
the cells with distinct kinetics for the different cytokines.
Combined LPS-INT-777 treatment significantly attenuated the
transient increase in mRNA levels for Tnfa, monocyte chemoat-
tractant protein 1 (Mcp-1), Il-6, and Il-1b (Figures 1G–1J).
TGR5 Inhibits NF-kB Activation via cAMP Signaling
To gain more insight into the mechanism through which TGR5
activation suppressed inflammatory cytokine production, we748 Cell Metabolism 14, 747–757, December 7, 2011 ª2011 Elsevierassessed the activation of two major proinflammatory transcrip-
tion factors, i.e., c-Jun, a component of AP-1, and nuclear factor
kB (NF-kB) by western blotting in RAW264.7 macrophages. As
expected, total c-Jun levels as well as phosporylation of c-Jun
were increased upon LPS stimulation of cells. TGR5 activation,
however, did not modulate LPS-induced phosphorylation of
c-Jun (Figure 2A). LPS also induced the nuclear translocation
of p65, a hallmark of activation of NF-kB signaling (Figure 2A).
In contrast to the phosphorylation of c-Jun, which remained
unchanged, p65 translocation was significantly blunted by
TGR5 activation with INT-777 (Figures 2A and 2B). This inhibitory
effect of INT-777 was furthermore attenuated by the adenylyl
cyclase inhibitor SQ22536, implying involvement of the cAMP
pathway (Figures 2A and 2B). To get more mechanistic insight
into the inhibitory effect of INT-777 on p65 translocation, we
studied phosphorylation of IkBa, a substrate of IkB kinase
(IKK), and NF-kB-p65 DNA binding activity to its response
element. In line with the decreased nuclear NF-kB-p65 localiza-
tion, INT-777 decreased both IkBa phosphorylation and NF-kB-
p65 DNA binding activity (Figures 2C–2E).
WealsomeasuredNF-kB transcriptional activity by transfecting
RAW264.7 macrophages with a NF-kB reporter plasmid contain-
ing the consensus NF-kB response element. In line with the find-
ings on p65 nuclear translocation, NF-kB transcriptional activity
was inhibited in LPS-treated macrophages in response to TGR5
activation or overexpression (Figure 2F), and was conversely
increased upon TGR5 silencing (Figure 2G). In agreement with
the cAMP-dependent effects of TGR5 on p65 nuclear transloca-
tion, SQ22536, as well as another adenylyl cyclase inhibitor, 2050-
dideoxyadenosine, reversed the effects of TGR5 on NF-kB tran-
scriptional activity (Figure 2H). Furthermore, INT-777 also inhibited
inflammation in RAW264.7 cells stimulated with TNFa, demon-
strating that the effect of INT-777 does not depend solely on LPS
stimulation (Figures S2A and S2B). As b-arrestin-2 signaling has
been implied in mediating anti-inflammatory effects of GPCRs
(Oh et al., 2010;Wang et al., 2011), we knocked down b-arrestin-2
in RAW264.7 cells using short hairpin RNA (shRNA) constructs
(Figure S2C), but were unable to couple the anti-inflammatory
effect of TGR5 activation to this molecule (Figures S2D and S2E).
To further explore the role of TGR5 in the inhibition of NF-kBwe
generated a mutant of the mouse TGR5 protein (TGR5-A217P).
Human TGR5 containing this mutation is unable to activate
cAMP-CREB signaling, presumably because the mutation is
located in a loop important for G protein interaction (Hov et al.,
2010). Expression of both wild-type and mutant TGR5 protein
was confirmed in CHO cells using our TGR5 antibody (Figures
3A–3I). TGR5-A217P did not enhance CREB activity in response
to activation with INT-777, suggesting that it was incapable to
induce cAMP signaling (Figure 3J). The TGR5-A217P mutant
was then used to assess NF-kB activity in the presence of ectop-
ically expressed p65. Interestingly, while the TGR5 wild-type
protein robustly inhibited NF-kB transcriptional activity, the
TGR5-A217P mutant failed to modulate NF-kB activity (Fig-
ure3K), further establishing that theTGR5-cAMP-NF-kBpathway
is critical for the inhibitionof cytokineproduction inmacrophages.
TGR5 Activation Inhibits Oxidized LDL Uptake
Besides inflammation, foam cell formation of macrophages is
a key event in the initiation of atherosclerosis. It has beenInc.
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Figure 1. The TGR5 Agonist INT-777 Inhibits
Macrophage Inflammation
(A) cAMP induction in primary macrophages iso-
lated from Tgr5/ and Tgr5+/+micemeasured 1 hr
after stimulation with vehicle (white bars) or 3 mM
INT-777 (black bars; n = 3).
(B) Intracellular calcium flux in primary macro-
phages isolated from Tgr5/ and Tgr5+/+ mice
measured 30 s after addition of 3 mM INT-777
(n = 3).
(C and D) mRNA expression (C) and protein
secretion (D) of TNFa in primary macrophages
isolated from Tgr5+/+ (white bars) or Tgr5/ (black
bars) mice in response to stimulation with
100 ng/ml LPS for 6 hr (n = 3).
(E and F) mRNA (E) and protein (F) levels of TNFa in
macrophages isolated from Tgr5 transgenic mice
(black bars) and wild-type mice (white bars) stim-
ulated with 100 ng/ml LPS for 6 hr in combination
with treatment of 30 mM INT-777.
(G–J) Tnfa (G), Mcp-1 (H), Il-6 (I), and Il-1b (J)
cytokine mRNA in response to 100 ng/ml LPS
(triangles) or not stimulated (squares) treated with
30 mM INT-777 (black) or control-treated (white) in
RAW264.7 macrophages (n = 3).
All conditions are present at all time points. Results
represent the mean ± SEM. * indicates statistically
significant, p < 0.05. See also Figure S1.
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TGR5 Inhibits Atherosclerosisdescribed that inhibition of NF-kB in macrophages reduces lipid
loading and foam cell formation, which could suggest that TGR5
inhibits lipid loading via this pathway (Ferreira et al., 2007). To
gain more insight into effects of TGR5 in lipid loading and foam
cell formation, we investigated whether TGR5modulates macro-
phage expression of scavenger receptor A (SR-A) and cluster of
differentiation 36 (CD36), both involved in scavenging modified
forms of LDL and foam cell formation (Febbraio et al., 2000; Su-
zuki et al., 1997). Interestingly, Sr-a as well asCd36mRNA levels
were higher in macrophages isolated from Tgr5/mice, relative
to Tgr5+/+ macrophages, and were reduced in Tgr5+/+ macro-
phages in response to INT-777 (Figures 4A and 4B). In line with
these observations, DiI-labeled oxidized LDL loading was
decreased upon INT-777 exposure in macrophages of wild-
type mice, but not in TGR5/mice (Figures 4C and 4D–4I), sug-
gesting that TGR5 inhibits macrophage foam cell formation.Cell Metabolism 14, 747–757,TGR5 Activation Inhibits
Atherosclerosis
The inhibitory effects of TGR5 activation
on inflammation and oxidized LDL
loading in macrophages suggested that
TGR5 could attenuate the development
of atherosclerosis. To investigate this
hypothesis, we first crossbred the
Tgr5/ animals to atherosclerosis-sus-
ceptible Ldlr/ mice to generate cohorts
of Ldlr/Tgr5+/+ and Ldlr/Tgr5/
littermates. These cohorts were then
used to further explore the effect of
TGR5 activation on the development of
atherosclerotic lesions. INT-777 wasadmixed to the atherogenic diet for 12 weeks at a dose sufficient
to reach an intake of 30 mg/kg/day. Food intake was equal
between the INT-777- and the control-treated groups as evalu-
ated by 24 hr home cage monitoring (data not shown). In line
with previous studies (Thomas et al., 2009; Watanabe et al.,
2006), treatment of INT-777 tended to reduce body weight and
plasma glucose of Ldlr/Tgr5+/+, but not of Ldlr/Tgrr5/
animals (Figures S3A and S3B). Furthermore, white blood cell
populations were not significantly different between the geno-
types or between control and INT-777 treatment (Figure S3C).
We observed a significant reduction in vascular lesion forma-
tion in the aortic root of INT-777-treated Ldlr/Tgr5+/+ mice
(Figures 5A–5C). This reduction, however, was not observed in
Ldlr/Tgr5/ mice, indicating that the protective effect of
INT-777 was TGR5 dependent (Figures 5A–5E). Cholesterol is
a major contributing factor to the development of atheroscleroticDecember 7, 2011 ª2011 Elsevier Inc. 749
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Figure 2. TGR5 Activation Inhibits NF-kB Activation via cAMP Signaling
(A) Western blot of C-Jun, phosphorylated c-Jun (P-C-Jun) with tubulin as loading control, and NF-kB p65 western blot of nuclear extract with PARP-1 as loading
control of RAW264.7 macrophages treated with 100 ng/ml LPS for 3 hr in combination with 100 mM SQ22536 and 30 mM INT-777 (n = 3).
(B) Quantification of western blot band intensity of p65 corrected for the intensity of PARP-1 with image-analysis software.
(C) Western blot of phosphorylated IkBa, total IkBa, and tubulin as loading control of lysate of RAW264.7 macrophages treated with 100 ng/ml LPS for 1 hr in
combination with 30 mM INT-777 (n = 3).
(D) Quantification of western blot band intensity of IkBa corrected for the intensity of tubulin with image-analysis software.
(E) NF-kB-p65 binding activity to its DNA response element after 3 hr LPS stimulation.
(F–H) LPS-induced (6 hr) NF-kB transcriptional activity in RAW264.7 macrophages electroporated with the NF-kB reporter plasmid in combination with elec-
troporation of TGR5 (F) or shTGR5 (G) in the presence of 30 mM INT-777 (black bars) or vehicle (white bars; n = 3). LPS-induced NF-kB transcriptional activity in
RAW264.7 macrophages electroporated with the NF-kB reporter plasmid in combination with 30 mM INT-777 treatment or vehicle in the presence of 100 mM
SQ22536 (gray bars), 20 mM 20, 50-dideoxyadenosine (black bars) or control conditions (white bars; n = 3) (H).
Results represent the mean ± SEM. * indicates statistically significant, p < 0.05. See also Figure S2.
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TGR5 Inhibits Atherosclerosislesions and differences in plasma levels between control and
INT-777-treated Ldlr/Tgr5+/+ mice could potentially account
for the observed effects. In line with the dysfunctional LDL
uptake in Ldlr/mice, plasma cholesterol levels were extremely
high in all experimental groups (Figure 5F). INT-777, however,
did not affect the total levels of cholesterol or triglycerides in
the two genotypes (Figures 5F and 5G). To get more insight
into the action of INT-777 on vascular lesion formation, we also750 Cell Metabolism 14, 747–757, December 7, 2011 ª2011 Elsevieranalyzed intraplaque inflammation by performing laser capture
microdissection of the lesions in the aortic root (Figures S3D–
S3F). In agreement with our previous observations, Tnfa and
Il-1b mRNA levels were significantly decreased in plaques of
INT-777 treated as compared to untreated Ldlr/Tgr5+/+
mice, whereas this effect of INT-777 was not observed in the
Ldlr/Tgr5/ mice (Figures 5H and 5I). Interestingly, mRNA
levels of the chemokines, Mcp-1 and Ccl5, showed a similarInc.
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Figure 3. The TGR5 Mutant TGR5-A217P,
Defective in Inducing cAMP Signaling, Fails
to Inhibit NF-kB Activity
(A–I) Confocal images of CHO cells transfected
with empty vector (A–C), mouse TGR5 (D and F),
and TGR5-A217P mutant (G–I) stained with DAPI
(B, E, and H), stained for TGR5 (A, D, and G), or
shown as merged images (C, F, and I).
(J) CREB transcriptional activity in CHO cells
transfected with both a CRE reporter and TGR5
wild-type (gray squares) or TGR5-A217P mutant
(black triangles) in response to INT-777 (n = 3).
(K) NF-kB transcriptional activity in CHO cells
transfected with the NF-kB reporter plasmid in
combination with empty vector (white bars), TGR5
(gray bars), and TGR5-A217P (black bars) with or
without NF-kB p65 cotransfection (n = 3).
Results represent the mean ± SEM. * indicates
statistically significant, p < 0.05.
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TGR5 Inhibits Atherosclerosisresponse upon INT-777 treatment (Figures S3G and S3H).
Further to this, we analyzed plaque composition, by performing
stainings for smooth muscle cell a-actin (ASMA) to detect
smooth muscle cells (SMCs), MAC3 to detect macrophages,
and Sirius red to stain collagen, which are major constituents
of atherosclerotic lesions (Figures 6A–6L). Quantification of
these stainings with image-analysis software revealed no
changes in SMC or collagen content but indicated a reduced
macrophage content in plaques derived from INT-777 treated
Ldlr/Tgr5+/+ mice as compared to untreated mice, whereas
this reduction in macrophage content was not observed in
Ldlr/Tgr5/ animals (Figures 6M–6O). Taken together, these
data indicate that TGR5 activation inhibits vascular lesion forma-
tion and that this process is associated with reduced intraplaque
inflammation and decreased macrophage content.
INT-777 Inhibits Atherosclerosis through Activation
of TGR5 in Leukocytes
To further confirm that the inhibition of atherosclerosis by
INT-777 is mediated by leukocytes, we performed bone marrow
transplantations to generate chimeric Ldlr/ animals carrying
bone marrow of either Tgr5+/+ or Tgr5/ mice. After the bone
marrow transplantations, mice were fed an atherogenic diet for
8 weeks, with or without the addition of INT-777 at a dose of
30 mg/kg/day. Examination of genomic DNA, isolated from
circulating white blood cells, indicated that the transplanted
animals were highly chimeric, as evidenced by the genotype
observed in the Tgr5 and Ldlr alleles (Figures 7A and 7B). This
was furthermore confirmed by quantitatively measuring wild-
type Ldlr mRNA levels, which indicated that animals reached
70%–95% of chimerism (data not shown). Furthermore, analysis
of white blood cell populations did not show any significant
changes (Figure S4A). In addition, total plasma triglycerides
and cholesterol were similar between the groups (Figures S4B
and S4C). Upon assessment of atherosclerosis in the aortic
root, a first observation was that, Ldlr/ mice transplanted
with bone marrow of Tgr5+/+ mice developed less vascularCell Mlesions upon INT-777 treatment (Figures 7C–7G), which
confirmed the robust inhibitory effect of INT-777 on the develop-
ment of atherosclerosis (see Figure 5). This beneficial effect of
INT-777 on plaque formation was totally lost in Ldlr/ mice
transplanted with Tgr5/ bonemarrow (Figures 7C–7G). Collec-
tively, these data demonstrate that the effect of INT-777 on
atherosclerosis is mediated through TGR5 activation in
leukocytes.
DISCUSSION
In this study, we demonstrate that activation of the membrane
bile acid receptor TGR5 protects against the development of
atherosclerosis. TGR5 is expressed in primary macrophages
and is responsive to INT-777, a semisynthetic BA that specifi-
cally activates TGR5. The inhibition of cytokine production
observed in INT-777 treated macrophages was dependent on
the activation of the cAMP-NF-kB signaling pathway, and is in
line with other observations demonstrating that cAMP inhibits
NF-kB activity (Minguet et al., 2005; Parry and Mackman,
1997). Moreover, TGR5 reduced oxidized LDL uptake in macro-
phages, which could contribute to the antiatherogenic effects of
INT-777. Most importantly, TGR5 activation inhibits the develop-
ment of atherosclerosis in Ldlr/ mice fed a high-cholesterol
diet, which is in line with the attenuation of inflammation and
oxidized LDL uptake observed in cultured macrophages. The
inhibition of atherosclerosis in Ldlr/ mice by TGR5 agonist
treatment was associated with decreased intraplaque inflamma-
tion and caused by the activation of TGR5 in leukocytes, as
concluded from experiments with bone marrow transplantations
of Tgr5/ and Tgr5+/+ donors.
Macrophage inflammation is central to almost all aspects that
contribute to the development of the atherosclerotic lesion,
starting from the initiation of atherosclerosis up to plaque rupture
that results in the induction of the coagulation cascade. In one of
the initial reports on the identification of TGR5 as a BA sensor,
the receptor was suggested to modulate the inflammatoryetabolism 14, 747–757, December 7, 2011 ª2011 Elsevier Inc. 751
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Figure 4. TGR5 Inhibits Oxidized LDL
Uptake
(A and B) Sr-a (A) and Cd36 (B) mRNA expression
in macrophages isolated from Tgr5+/+ and Tgr5/
mice in response to INT-777 treatment (black bars)
or control-treated (white bars; n = 3).
(C) Fluorescence of DiI-labeled oxidized LDL ex-
tracted from macrophages isolated from Tgr5+/+
and Tgr5/ mice in response to INT-777 (black
bars) or control conditions (white bars; n = 3).
(D–I) Confocal fluorescent images of macro-
phages from Tgr5+/+ (D, E, and F) and Tgr5/
(G, H, and I) mice treated with DiI-labeled oxidized
LDL (E, F, H, and I) in combination with INT-777
treatment (F and I).
Results represent the mean ± SEM. * indicates
statistically significant, p < 0.05.
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TGR5 Inhibits Atherosclerosisresponse (Kawamata et al., 2003). In that study, BA treatment of
rabbit alveolar macrophages increased cAMP production, and
decreased phagocytic activity as well as TNFa secretion. In
agreement with this, THP-1 cells overexpressing TGR5 showed
similar effects in response to BAs, which was not observed in un-
transfected THP-1 cells. Similarly, a report in rat Kupffer cells
demonstrated that BAs induce cAMP levels and decrease
inflammatory cytokine production, suggestive for a role of
TGR5 in this process (Keitel et al., 2008). In the current study,
using primary macrophages isolated from mice with both
TGR5 loss of function (Tgr5/ mice) and gain of function
(Tgr5-overexpressing transgenic mice), we unequivocally
demonstrate that TGR5 activation in macrophages potently
inhibits inflammation by affecting cAMP- and NF-kB signaling.
Furthermore, we show that the TGR5-cAMP-NF-kB signaling
pathway modulates cytokine secretion and that several aspects
of inflammation are perturbed in mice lacking TGR5, providing
in vivo proof that TGR5 is an anti-inflammatory actor. These
data are in line with a recent report that focuses on liver inflam-
mation and demonstrates that TGR5 inhibits NF-kB inflamma-
tion in macrophages and Kupffer cells. In this study, it was
suggested that the decrease in NF-kB activity in response to
TGR5 activation involves increased b-arrestin-2 signaling
(Wang et al., 2011).While b-arrestin-2 is known as an established
regulatory component of GPCR signaling (Pierce et al., 2002),
our data argue against a role for b-arrestin-2, and rather support
a role of cAMP signaling to explain the anti-inflammatory activity
of TGR5 activation.752 Cell Metabolism 14, 747–757, December 7, 2011 ª2011 Elsevier Inc.In addition to reducing inflammation in
macrophages, TGR5 activation seems to
interfere, at least to a certain extent, with
the uptake of modified lipoproteins in
macrophages. Several endocytic path-
ways in macrophages can contribute to
the focal buildup of cholesterol in arteries,
which precedes atherosclerotic plaque
formation (Rocha and Libby, 2009). In line
with a contribution of macrophage lipid
loading, we indeed observed a reduced
expression of both Cd36 and Sr-a, two
receptors involved in the endocytosis ofmodified forms of LDL upon TGR5 activation. Although the inhibi-
tion of foam cell formation could in part be a consequence of
reduced expression of Sr-a and Cd36, it could also be a conse-
quence of the inhibition of NF-kB, which is known to inhibit foam
cell formation (Ferreira et al., 2007). In this context, it is worth to
mention that the atherogenic role of SR-A and CD36 has been
challenged. This is exemplified by a report demonstrating that
ApoE/Sr-a/ or ApoE/Cd36/ knockout mice did not
show a reduction in atherosclerosis, despite the presence of
reduced macrophage cholesterol ester accumulation (Moore
et al., 2005). The precise implication of the downregulation of
Sr-a and Cd36, as well as the inhibition of macrophage foam cell
formation by TGR5 in vitro with regard to atherosclerotic plaque
formation, therefore deserves further study.
Another interesting aspect relates to the nature of the plaque
composition between control- and INT-777-treated animals.
While most of the constituents of the atherosclerotic plaques
were similar in both conditions, macrophage content was signif-
icantly reduced, as well as the intraplaque inflammation as-
sessed on isolated plaques of INT-777-treated animals. Since
these parameters have a predictive function in the progression
and destabilization of atherosclerotic plaques (Libby et al.,
1996), treatment with TGR5 agonists is likely to result in a more
stable plaque phenotype, and could hence be of relevance to
reduce the risk of plaque rupture and occurrence of subsequent
myocardial infarctions. Investigation of intraplaque expression
of Mcp-1 and Ccl5 could indicate that the reduced expression
of these chemokines contributed to decreased plaque
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Figure 5. TGR5 Activation Inhibits Atherosclerosis
(A) Plaque size in the aortic root of Ldlr/Tgr5+/+ (white symbols) and Ldlr/Tgr5/ animals (black symbols) treated with INT-777 (squares) or control-treated
(circles; n = 8–9).
(B–E) Oil red O staining of atherosclerotic lesions in the aortic root of Ldlr/Tgr5+/+ (B and C) or Ldlr/Tgr5/ animals (D and E) treated with INT-777 (C and E) or
control treated (B and D).
(F and G) Plasma cholesterol (F) and triglycerides (G) of Ldlr/Tgr5+/+ and Ldlr/Tgr5/ animals treated with INT-777 (black bars) or control treated (white bars;
n = 8–9).
(H and I) mRNA levels of Tnfa (H) and Il-1b (I) in aortic root lesions captured by laser capture microdissection of Ldlr/Tgr5+/+ and Ldlr/Tgr5/ animals treated
with INT-777 (black bars) or control treated (white bars; n = 3).
Results represent the mean ± SEM. * indicates statistically significant, p < 0.05. See also Figure S3.
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TGR5 Inhibits Atherosclerosismacrophage content (Zernecke and Weber, 2010). What is most
striking, however, is the critical contribution of the immune-
modulating cells to the atheroprotective action of TGR5. TGR5
activation is known to have a beneficial impact on various
aspects of the metabolic syndrome by boosting energy metabo-
lism and improving both glucose tolerance and lipid homeostasis
(reviewed in (Pols et al., 2011). The insulinotropic hormone
GLP-1, for instance, whose secretion is triggered by TGR5 acti-
vation in enteroendocrine cells (Katsuma et al., 2005; Thomas
et al., 2008a), was recently shown to protect against atheroscle-
rosis via a mechanism that involves cAMP induction in macro-
phages (Arakawa et al., 2010). Although it could be very well
possible that such systemic effects could contribute to the athe-
roprotective actions of TGR5 activation, the outcome of our
bone-marrow transplant studies unequivocally establish the
predominant role of TGR5 in leukocytes to explain this effect.
In view of the promise of TGR5 as a potential therapeutic
target in the metabolic syndrome (Pols et al., 2011; Thomas
et al., 2008b, 2009; Watanabe et al., 2006), drug development
efforts around this target are intense (Evans et al., 2009; Herbert
et al., 2010). It is therefore expected that in addition to INT-777,Cell Mseveral selective and potent non-BA TGR5 agonists will become
available in the near future. Furthermore, many natural
compounds have been described to activate TGR5, which
include triterpenoid compounds of plant origin, such as olea-
nolic, ursolic, and betulinic acid (Genet et al., 2010; Sato et al.,
2007). With the prospect of using TGR5-specific natural
and synthetic agonists to prevent and/or treat the metabolic
syndrome in humans, our study suggests that such compounds
also may have beneficial effects in the context of atheroscle-
rosis, another important facet of the metabolic syndrome.
Despite these potentially optimistic prospects, much more
work is required to elucidate the pleiotropic actions of
TGR5 and to assure that these beneficial effects observed in
mice translate into humans. Importantly, atherosclerosis in
humans is not identical to that observed in mouse models, and
the beneficial effects of TGR5 activation in this animal model
should be confirmed in human studies. Furthermore, the
suppression of the inflammatory response, although beneficial
within the context of chronic inflammatory diseases, such as
atherosclerosis and the metabolic syndrome, may weaken
host defense systems. As for any novel drug target, theetabolism 14, 747–757, December 7, 2011 ª2011 Elsevier Inc. 753
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Figure 6. TGR5 Modulates Plaque Macro-
phage Content
(A–L) ASMA staining (A–D), MAC3 staining
(E–H), and Sirius red staining (I–L) to detect
smooth muscle cells, macrophages, and colla-
gen, respectively, in aortic root lesions of
Ldlr/Tgr5/ and Ldlr/Tgr5+/+ animals treated
with or without INT-777.
(M–O) Quantification of ASMA (M), MAC3 (N), and
Sirius red (O) staining area with image-analysis
software of aortic root lesions of Ldlr/Tgr5/
and Ldlr/Tgr5+/+ animals treated with (black
bars) or without INT-777 (white bars; n = 8–9).
Results represent the mean ± SEM. * indicates
statistically significant, p < 0.05.
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TGR5 Inhibits Atherosclerosisdevelopment of TGR5 agonists therefore needs to proceed with
caution and carefully balance the therapeutic benefits and
potential side effects associated with the target (Lavoie et al.,
2010; Li et al., 2011; Perides et al., 2010; reviewed in Pols
et al., 2011). Taken together, we demonstrate here that the acti-
vation of TGR5 prevents atherosclerotic lesion formation through
an effect on leukocytes in Ldlr/mice, a commonly usedmouse
model of atherosclerosis. Inhibition of macrophage NF-kB
signaling, as well as a reduction of macrophage foam cell forma-
tion, may both contribute to the protective effects of TGR5
activation in the context of the atherosclerotic plaque. In combi-
nation with its beneficial impact on energy homeostasis and
glucose tolerance, the significant immune modulating function
of TGR5 activation in the prevention of atherosclerosis further
bolsters the importance of TGR5 as a potentially promising target
to prevent and/or treat many facets of the metabolic syndrome.
EXPERIMENTAL PROCEDURES
Confocal Imaging
For confocal imaging, cells were grown on Labtek II chamber slides (Nunc) and
fixed with Shandon Formal Fixx (Thermo Scientific). Nuclei were subsequently
stained with 40,6-diamidino-2-phenylindole (DAPI), and cells were embedded
with 1,4-diazabicyclo(2.2.2)octane (DABCO). Images were acquired with
a LSM700 confocal microscope (Zeiss). Our TGR5 homemade antibody was
raised in rabbitsby immunizationagainst thepeptide306 to322ofmouseTGR5.
Lipid Loading in Macrophages
To investigate lipid loading, primary macrophages were cultured in medium
containing 1% FCS in which 50 mg/ml DiI-OxLDL (BT-920; Biomedical Tech-754 Cell Metabolism 14, 747–757, December 7, 2011 ª2011 Elsevier Inc.nologies) was added. After 8 hr of incubation, cells
were fixed using Shandon Formal Fixx (Thermo
Scientific), and confocal images were made. Alter-
natively, cells were washed with PBS and DiI-
labeled oxidized LDL was extracted from cells
with isopropanol, after which fluorescence was
measured in the Victor X4 (PerkinElmer) to quantify
the amount of DiI-labeled oxidized LDL uptake.
Real-Time qRT-PCR
RNA was isolated from cells with TRI Reagent
(Ambion), after which complementary DNA
(cDNA) was synthesized (QIAGEN). Real-time
qRT-PCR was performed with SYBR green
(Roche) in the Lightcycler 480 II (Roche). AllmRNA expression levels were corrected for expression of the housekeeping
gene 36B4 or b2-microglobulin. Used primer sequences are available upon
request.
Western Blotting and NF-kB DNA Binding Activity
Western blotting was performed with antibodies against p65 (C-20), tubulin
(B-7), and PARP-1 (N-20; Santa Cruz Biotechnology), C-Jun (9162) and phos-
phorylated-C-Jun (9261), IkBa (4814), phospho-IkBa (Ser32/36; 5A5; Cell
Signaling), and HRP-labeled anti-rabbit secondary antibodies (Cell Signaling).
The intensities of the protein bands were quantified with ImageJ software.
NF-kB-p65 DNA binding activity was assessed with a TransAm transcription
factor ELISA (Active Motif).
Reporter Assays
RAW264.7 macrophages were transfected by electroporation with the Amaxa
device (Lonza). Transfected vectors include the full-length mouse TGR5
(Watanabe et al., 2006), NF-kB reporter plasmid containing the NF-kB
consensus sequence (Clontech), CMV-b-gal expression vector to correct for
transfection efficiency (Clontech). Luciferase activity was measured with
the luciferase assay system (Promega) in the Victor X4 (PerkinElmer). The
CREB-luciferase reporter construct (Stratagene) contained four copies of the
CRE enhancer sequence and was transfected in CHO cells with or without
(mutant) TGR5 using JetPEI (Polyplus Transfection).
FACS
Peritoneal cell populations isolated 5 days after intraperitoneal thioglycollate
injection were FACS sorted with the FACSAria II (BD Biosciences) with
E-Fluor450-labeled anti-mouse CD45R, Phycoerythrin (PE)-Cy7-labeled
anti-mouse CD11b, PE-labeled anti-mouse TCRb, and Allophycocyanin
(APC) anti-mouse GR1 (all from EBioscience) to separate different inflam-
matory cell populations present in the peritoneal cavity of 12-week-old
C57Bl/6 mice. The FcR was blocked with anti-FcR antibodies (Fc g
AC D E
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Figure 7. INT-777 Inhibits Atherosclerosis through Activation of TGR5 in Leukocytes
(A and B) PCR products showing the genotype of the Ldlr (A) and Tgr5 (B) locus in genomic DNA isolated from circulating white blood cells of Ldlr/ animals as
well as LDLR/ animals transplanted with Tgr5+/+ and Tgr5/ bone marrow.
(C) Plaque size in the aortic root of Ldlr/ animals transplanted with Tgr5+/+ (white symbols) or Tgr5/ bone marrow (black symbols) treated with INT-777
(squares) or control-treated (circles; n = 9–12).
(D–G) Oil red O staining of atherosclerotic lesions in the aortic root of Ldlr/ animals carrying Tgr5+/+ (D and E) or Tgr5/ bone marrow (F and G) treated with
INT-777 (E and G) or control treated (D and F).
* indicates statistically significant, p < 0.05. See also Figure S4.
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TGR5 Inhibits AtherosclerosisRIIb/CD16-2 [derived from hybridoma 2.4G2]). Sorted cells were used for
RNA isolation.
Bone Marrow Transplantation Study
Mice used as bone marrow transplantation recipients were 8- to 10-week-
old Ldlr/ animals (strain B6.129S7-Ldlrtm1Her/J; Jackson Research) that
were subjected to total body X-irradiation of 850 Rad (RS2000 Irradiator)
split into two exposures after NK cells were depleted by injection of the
mice with the monoclonal PK136 antibody. Tgr5/ or Tgr5+/+ littermates
aged 4 to 6 weeks were used as bone marrow donors. After 4 weeks of
recovery, which included treatment with Baytril (Bayer) and Dafalgan
(Bristol-Myers Squibb), mice were fed the atherogenic diet (TD94059; Har-
lan) containing 30 mg/kg INT-777 for 8 weeks. Chimerism was assessed by
isolating genomic DNA from white blood cells 8 weeks after transplanta-
tion with the following primers for the Ldlr gene: primer 1 (common),
50-CCATATGCATCCCCAGTCTT-30; primer 2 (WT), 50-AATCCATCTTGTTC
AATGGCC-30; and primer 3 (Mut), 50-GCGATGGATACACTCACTGC-30).
Tgr5 deletion in the white blood cells was confirmed with the following
primers: primer A (Del), 50-GATGGCTGAGAGGCGAAG-30; primer B
(common), 50-AGAGCCAAGAGGGACAATCC-30; and primer C (WT),
50-TGGGTGAGTGGAGTCTTCCT-30. Primers for Ldlr (primers 1 and 2) as
well as a calibration curve consisting of mixed DNA of Ldlr/ and wild-
type animals allowed qRT-PCR reactions to quantify chimerism. Ldlr gene
levels were corrected with primers against the myogenin gene (primer 1,
50-TTACGTCCATCGTGGACAGC-30; and primer 2, 50-TGGGCTGGGTGTT
AGCCTTA-30).Cell MLaser Capture Microdissection
Laser capture microdissection of lesions was performed on unfixed frozen
sections of the aortic root with the Autopix laser capture microdissection
device (Arcturus). Tissue used for RNA isolation with the PicoPure RNA isola-
tion kit (Arcturus) was derived from pooling of captured tissue from eight
consecutive sections of each lesion, after which cDNA was synthesized with
the VILO cDNA synthesis kit (QIAGEN). Lesions of three representative animals
per groups were used for laser capture microdissection.
Immunohistochemistry Stainings and Quantification
Antibodies against MAC3 (BP Pharmingen) and ASMA (1A4; Dako) were used
for immunohistochemistry to detect lesion macrophages and smooth muscle
cells. A Sirius red staining was performed to stain collagen. The FcR was
blocked with anti-FcR antibodies (Fc g RIIb/CD16-2 [derived from hybridoma
2.4G2]). The MAC3 staining was visualized with Vectastain Elite ABC Peroxi-
dase kit Rat IgG (Vector) and NovaRED substrate (Vector), and the Asma stain-
ing was visualized with KITMouse IgG (Immpress) and DAB substrate (Sigma).
Positive surface areaswere determinedwith ImageJ software using a color de-
convolution plug-in.
Cell Culture
Primary macrophages were isolated from the peritoneal cavity 5 days after thi-
oglycollate injection, plated in culture dishes, and washed 24 hr after plating to
discard nonmacrophage populations. Serum-starved macrophages were
stimulated with INT-777 in the presence of 0.1% bovine serum albumin. The
calcium flux was measured wth a Fluo-4 fluorescent probe (Molecular Probes)etabolism 14, 747–757, December 7, 2011 ª2011 Elsevier Inc. 755
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TGR5 Inhibits Atherosclerosisin the Victor X4 (PerkinElmer). Intracellular cAMPwasmeasured 1 hr after addi-
tion of INT-777 with a cAMP chemoluminescent immunoassay kit (Applied
Biosystems). SQ22536 and 20,50-dideoxyadenosine were bought from Sigma.
TNFa levels were quantified with Mouse TNFa ELISA Ready-SET-Go!
(eBioscience). RAW264.7 cells were transfected using electroporation (Lonza)
with the TGR5 silencing construct (Origene). b-arrestin-2 shRNA or control
shRNA constructs were cloned into the pENTR/U6 vector (Invitrogen);
sequences are available upon request.
Animals, Biochemistry, and Atherosclerosis Assessment
All animal studies were performed according to regulations issued by the
Swiss government. TGR5 genetic models were described earlier (Thomas
et al., 2009). The mice were backcrossed for ten generations with the
C57BL/6J strain, yielding congenic C57BL/6J Tgr5/ animals. The controls
that were used were littermates in all experiments. Mice were sacrificed
12 weeks after the initiation of the atherogenic diet (TD94059; Harlan), after
which the heart and aorta were perfused with PBS and subsequently fixed
(Shandon Formal Fixx, Thermo Scientific). Atherosclerosis was assessed by
anOil redO staining of the aortic root and quantifiedwithMetaMorph software.
Biochemistry parameters were measured with the appropriate kits in the
COBAS C111 (Roche). For the in vivo LPS study, mice were intraperitoneally
injected with 100 mg LPS, and blood was taken from the tail vein. TNFa levels
were quantified with Mouse TNFa ELISA Ready-SET-Go! (eBioscience). Blood
cell counts were determined with Advia2120 (Siemens Healthcare
Diagnostics).
Statistical Analysis
The Student’s t test was used to calculate the statistical significance. In case of
multiple testing (i.e., the comparison of more than two groups), this test was
preceded by the ANOVA test. p < 0.05 was considered statistically significant.
Results represent the mean ± SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures and can be found with this
article online at doi:10.1016/j.cmet.2011.11.006.
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